Effect of direct acting antiviral treatment (DAAs), as a new treatment of chronic viral hepatitis C on patients with heart failure

Ibrahim, Alaa M.; Ali, Hisham A.; Ahmad, Hazem . M. A.; Mounir, Mena S.

doi:10.21608/mjmr.2022.221009

Effect of direct acting antiviral treatment (DAAs), as a new treatment of chronic viral hepatitis C on patients with heart failure

Document Type : Original Article

Authors

¹ Department of Cardiology, Faculty of Medicine, Minia University

² Department of Internal medicine, Faculty of Medicine, Minia University.

³ Department of Cardiology, Faculty of Medicine, Minia University.

10.21608/mjmr.2022.221009

Abstract

Introduction: Hepatitis C virus (HCV) infection is a persistent viral infection of the liver and
considered as a considerable health dilemma globally especially in Egypt. Treatment for chronic
hepatitis C virus infection is evolving from interferon (IFN)-based therapy to direct-acting antiviral
(DAA) agents. Cardiovascular diseases (CVDs), which accounted for one-third of global deaths in
2015, are recognized as a major barrier to sustainable human development. Aim of the work: The
aim of this study is to evaluate the effect of new antiviral treatments regarding heart failure in patients
with chronic viral hepatitis “c”. Patients and Methods: This cohort study was carried out on 100
patients with chronic heart failure and candidate for DAA therapy. Cases were taken and divided into:
Results: The DAAs used in combination regimen with ribavirin do not significantly affect the
cardiovascular system.

Keywords

Main Subjects